Takeda pays $5.2bn for Iclusig developer Ariad Pharmaceuticals
Executive Summary
Takeda Pharmaceutical Co. Ltd., via a newly created entity called Kiku Merger Co. Inc., acquired publicly traded Ariad Pharmaceuticals Inc. (oncology therapeutics) for $5.2bn, paying $24 in cash per share (an 89% premium).
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Acquisition
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice